Gilda de la Calle, MD
General Practice · Hialeah, FLNPI 1174622682
Payments from drug & device makers
Across 590 payments — averaging $2454.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$833K
- GSK$251K
- Genentech, Inc.$214K
- Vanda Pharmaceuticals Inc.$51K
- Sanofi US Services Inc.$49K
- Alnylam Pharmaceuticals Inc.$26K
- plus $24K from 36 others
Across 16 payments — averaging $839.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Celltrion, Inc.$7K
- Eli Lilly$6K
- Ichnos Glenmark Innovation Inc$907
What the payments were for
- Food & beverage$11,906100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,448,054 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 78 | $85,471 |
| OzempicSemaglutide | 77 | $80,187 |
| EliquisApixaban | 66 | $60,816 |
| FarxigaDapagliflozin Propanediol | 70 | $58,647 |
| XareltoRivaroxaban | 59 | $57,868 |
| VascepaIcosapent Ethyl | 97 | $54,493 |
| TrulicityDulaglutide | 45 | $49,948 |
| ProliaDenosumab | 18 | $30,938 |
| JanuviaSitagliptin Phosphate | 20 | $28,606 |
| LinzessLinaclotide | 28 | $27,587 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 29 | $24,761 |
| EntrestoSacubitril/Valsartan | 28 | $22,187 |
| TradjentaLinagliptin | 23 | $21,588 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $19,875 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $15,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr, Synjardy | $405 | $159,836176 claims |
| Novo NordiskOzempic | $493 | $80,18777 claims |
| AstraZenecaFarxiga, Symbicort | $8,605 | $74,004130 claims |
| PfizerEliquis | $121 | $60,81666 claims |
| Johnson & JohnsonXarelto | $1,088 | $57,86859 claims |
| Lilly USA, LLCTrulicity | $661 | $49,94845 claims |
| MerckJanuvia, Janumet | $55 | $48,48133 claims |
| AbbVieLinzess, Synthroid | $3,218 | $33,42788 claims |
| AmgenProlia | $106 | $30,93818 claims |
| NovartisEntresto | $190 | $22,18728 claims |
| GSKBreo Ellipta | $251,401 | $15,35135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Hialeah
- Frank AlvarezHialeah$13.6M
- Manuel SanchezHialeah$5.2M
- Gustavo TorresHialeah$3M
- Maria NualartHialeah$2.7M
- Agustin RivasHialeah$2M
- Heliodoro RuizHialeah$1.6M
- Idania FernandezHialeah$1.5M
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.